Enhanced Glucokinase Activator Therapies for Renal Impairment
Legal Citation
Summary of the Inventive Concept
Improved glucokinase activator treatments for diabetes with renal impairment, addressing limitations in existing therapies through sustained-release formulations, personalized dosing regimens, and renal-protective agents.
Background and Problem Solved
The original patent disclosed glucokinase activator treatments for diabetes with renal impairment, but had limitations in dosing frequency, glucose level monitoring, and potential kidney damage. The new inventive concept addresses these limitations by introducing sustained-release formulations, wearable glucose level tracking, and renal-protective agents to enhance treatment efficacy and safety.
Detailed Description of the Inventive Concept
The new inventive concept comprises four key aspects: (1) a sustained-release formulation of the glucokinase activator to reduce dosing frequency, (2) a wearable device and computer program for tracking glucose levels and generating personalized dosing regimens, (3) a glucokinase activator composition with a renal-protective agent to minimize kidney damage, and (4) a genetic profiling method to identify subjects likely to benefit from glucokinase activator treatment. These enhancements improve treatment outcomes, reduce side effects, and enhance patient quality of life.
Novelty and Inventive Step
The new claims introduce non-obvious improvements over the original patent, including the use of sustained-release formulations, wearable glucose level tracking, and renal-protective agents. These innovations provide a significant advancement in the field of glucokinase activator therapies for diabetes with renal impairment.
Alternative Embodiments and Variations
Alternative embodiments may include different sustained-release formulations, varying wearable device designs, or alternative renal-protective agents. Variations may also include combining glucokinase activators with other diabetes treatments or integrating the wearable device with other health monitoring systems.
Potential Commercial Applications and Market
The enhanced glucokinase activator therapies have significant commercial potential in the diabetes treatment market, particularly for patients with renal impairment. The market is expected to grow as the prevalence of diabetes and kidney disease increases, and the new inventive concept is well-positioned to capture a significant share of this market.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically diabetes treatment and pharmacological interventions for renal impairment, requiring advanced degrees in pharmacology, biochemistry, or related medical sciences with expertise in drug delivery systems and metabolic disorders
Person of Ordinary Skill (PHOSITA) Profile
A researcher or clinical pharmacologist with advanced training in diabetes therapeutics, familiar with drug formulation techniques, glucose metabolism, and personalized medicine approaches
Obviousness Rationale
A person having ordinary skill would recognize that the disclosed variations represent predictable extensions of the source patent's core glucokinase activator treatment methodology. The PTD's innovations address known limitations in diabetes treatment for renally impaired patients through standard pharmaceutical engineering techniques. These modifications represent incremental improvements using well-established methodologies in drug delivery and personalized medicine.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,536 |
|---|---|
| Title | Glucokinase activator for treating diabetes with renal impairment |
| Assignee(s) | HUA Medicine (Shanghai) Ltd. |